Improve your Drug Development Success with Biomarkers
 |
|
|
Including biomarkers early on in the drug development process can make use of genomic and proteomic techniques, thereby increasing the probability that initial administration to humans will be safe, or help determine the relevance of animal findings in humans. In a clinical environment, such information can be used to exclude participants from trials, or monitor reactions to drugs in participants who may be at risk from a treatment. Join our experts at the 14th WRIB Virtual from June 15-29 to learn more about Altasciences' list of biomarkers and to understand how our integrated biomarker approach from preclinical to clinical can enhance the safety of new drugs, improve the assessment of promising drug candidates, as well as reduce the cost of developing drugs and bringing them to market. |
Fierce Biotech: Altasciences Continues to Beef Up its Exec Suite With Newly Appointed CMO
Contract Pharma: Altasciences Names Chief Medical Officer
Dr. Gaetano Morelli Named Chief Medical Officer at Altasciences
Laval, Quebec, June 9, 2020 – Altasciences announced today the appointment of Dr. Gaetano Morelli as Chief Medical Officer, effective May 14, 2020.
Dr. Morelli is a member of the College of Physicians of Québec, Canada, with over 30 years' medical experience and over 20 years' global clinical research background. He joined Altasciences in 2013 as a GI consultant and then signed on with Altasciences in 2017, first as Medical Advisor, then Clinical PI, and now Chief Medical Officer.
“Dr. Morelli’s work and decades of experience in clinical research and hospitals have been instrumental to our studies since joining us in 2017. As Chief Medical Officer, Dr. Morelli will continue to provide key insight to our teams in North America and to sponsors worldwide, as we navigate the complexities of early-phase drug development,” said Chris Perkin, CEO at Altasciences.
Prior to joining Altasciences, Dr. Morelli was the Global Medical Director at MDS Pharma for 10 years, overseeing five clinical sites in Canada, the U.S.A., and Ireland. Dr. Morelli is an Associate Professor of Medicine at McGill University, in Montreal. He also continues to be active staff at the McGill University Hospital Center. In addition, he is Director of Gastroenterology/GI Endoscopy at one of the McGill University affiliated hospitals. He has been Principal Investigator in numerous multi-national, multi-center clinical trials.
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
CONTACT:
Julie-Ann Cabana
Altasciences
514 601-9763
jcabana@altasciences.com
Dietary Biotin Interference in Hybrid LBA-LC-MSMS Assays Characterization, Impact, and Recommendations
ISSUE NO. 13 — Safety Pharmacology Studies - a Review
Click HERE to read the Altascientist
Selectivity, Selectivity, Selectivity - a New Dimension by Differential Mobility Spectrometry
Complimentary webinar to learn how Altasciences can tackle your most challenging bioanalytical assays by combining the high sensitivity of the SCIEX 6500+ TripleQuad with ion mobility technology to achieve next level detection limits with unprecedented selectivity.
NDA-Enabling Study Guide
|
|
|
Altasciences' specialists apply their decades of experience in designing, conducting, analyzing, and reporting on trials for regulatory submissions, across the spectrum of therapeutic areas. Unclear as to which studies may be required? Download our complimentary fact sheet or click below to learn more about the requirements for each study type. |
|
|
Utilizing Nano Particulate Formulations in the Delivery of Poorly Soluble Drugs
Safety Tolerability and Pharmacokinetics of GIC-1001 Following Multiple Ascending Doses Administrations Through an Adaptive First-in-Human Study in Healthy Volunteers